Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Cibc World Market Inc.

Cibc World Market Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO) by 6.2% during the fourth quarter, Holdings Channel.com reports. The firm owned 658,463 shares of the company’s stock after acquiring an additional 38,689 shares during the period. Cibc World Market Inc.’s holdings in Novo Nordisk A/S were worth $56,641,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also made changes to their positions in the company. International Assets Investment Management LLC lifted its holdings in Novo Nordisk A/S by 10,608.4% in the 3rd quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after purchasing an additional 1,796,635 shares in the last quarter. Mediolanum International Funds Ltd purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $98,765,000. Wellington Management Group LLP purchased a new position in shares of Novo Nordisk A/S during the 3rd quarter worth $42,017,000. World Investment Advisors LLC raised its holdings in shares of Novo Nordisk A/S by 2,655.9% during the 3rd quarter. World Investment Advisors LLC now owns 280,409 shares of the company’s stock worth $33,388,000 after acquiring an additional 270,234 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Novo Nordisk A/S by 71.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 475,490 shares of the company’s stock worth $57,413,000 after acquiring an additional 198,891 shares during the period. Institutional investors and hedge funds own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms have recently commented on NVO. UBS Group upgraded Novo Nordisk A/S from a “sell” rating to a “buy” rating in a report on Wednesday, January 8th. StockNews.com downgraded Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a research report on Sunday, December 29th. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating for the company in a research report on Monday, December 23rd. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. One equities research analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $145.25.

Novo Nordisk A/S Stock Performance

Novo Nordisk A/S stock opened at $85.33 on Friday. The stock’s 50-day moving average is $94.32 and its 200-day moving average is $113.82. The company has a market cap of $382.91 billion, a price-to-earnings ratio of 27.61, a price-to-earnings-growth ratio of 0.92 and a beta of 0.45. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. Novo Nordisk A/S has a 12 month low of $78.17 and a 12 month high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.